drugset / Trial / NCT03820518

Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia

NCT03820518

Phase 4 Unknown 100 enrolled Peking Union Medical College Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

X-linked hypophosphatemia (XLH) is the most common form of heritable rickets. Current treatments include active vitamin D metabolites (e.g. calcitriol) and phosphate salts. There is no consistent weight-based dosing of calcitriol and phosphate now. The primary objective of this study is to establish the efficacy of different dose of calcitriol combined with neutral phosphate in children with XLH.

Timeline

Start
2017-01-01
Primary completion
2021-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcitriol Small molecule 20 ng
Subject Calcitriol Small molecule 60 ng